Fidrisertib is under clinical development by Clementia Pharmaceuticals and currently in Phase II for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva). According to GlobalData, Phase II drugs for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Fidrisertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Fidrisertib overview

IPN-60130 (BLU-782) is under development for the treatment of fibrodysplasia ossificans progressiva. The drug candidate is administered through the oral route as a capsule. It acts by targeting Activin A receptor, type I (ACVR1) also known as ALK-2.

Clementia Pharmaceuticals overview

Clementia Pharmaceuticals (Clementia) is a clinical stage biopharmaceutical company that focuses on the development of treatments for rare bone disorders and other diseases. Its lead product candidate Palovarotene is used for the treatment of fibrodysplasia ossificans progressiva (FOP), dry eye disease and multiple osteochondromas (MO). Palovarotene is a novel retinoic acid receptor gamma agonist, and an oral therapy that prevents the abnormal new bone formation as well as fibrosis in a variety of tissues. The company partners with pharmaceutical companies, universities and other research institutes to develop its product portfolio. It has presence in the US and Canada. Clementia is headquartered in Montreal, Quebec, Canada.

For a complete picture of Fidrisertib’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.